American Century Companies
IRD

American Century Companies’s Opus Genetics IRD Stock Holding History

American Century Companies’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-65,911
Closed -$132K – 2965
2024
Q1 		$132K Buy
65,911
+5,654
+9% +$14.3K ﹤0.01% 2832
2023
Q4 		$181K Sell
60,257
-96
-0.2% -$284 ﹤0.01% 2722
2023
Q3 		$202K Buy
60,353
+32,263
+115% +$130K ﹤0.01% 2590
2023
Q2 		$122K Buy
+28,090
New +$133K ﹤0.01% 2648

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

American Century Companies's IRD Position: Q2 2024 in Review

American Century Companies sold out of Opus Genetics (IRD) in Q2 2024, closing a stake of 65,911 shares — an estimated $132K sold.

American Century Companies first reported a position in IRD in Q2 2023 and held it in 4 quarters. The position peaked at $202K in Q3 2023. 37 funds tracked by Wall St. Rank hold IRD as of Q2 2024.

  • American Century Companies reported no remaining Opus Genetics position as of Q2 2024 after selling out during the quarter.
  • American Century Companies sold 65,911 Opus Genetics shares in Q2 2024, an estimated $132K.
  • American Century Companies first reported a position in Opus Genetics in Q2 2023 and held it in 4 quarters.
  • American Century Companies's Opus Genetics position peaked at $202K in Q3 2023.
  • 37 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2024.

Based on American Century Companies's 13F filing for Q2 2024, filed 7 Aug 2024.